# Vertex Pharmaceuticals Incorporated – Consensus ‘buy’ rating and 5.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-consensus-buy-rating-and-5.2-upside-potential/4121131019
- Published: 2023-10-26T14:11:26+01:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** with ticker code (VRTX) have now 24 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The range between the high target price and low target price is between 456 and 
315 with the average target price sitting at $388.67. Given that the stocks previous
close was at $369.38 this is indicating there is a potential upside of 5.2%. Also
worth taking note is the 50 day moving average now sits at $353.89 and the 200 day
moving average is $333.04. The company has a market capitalization of 93.70B. The
stock price for the company is currently 363.04 USD

 The potential market cap would be $98,592,009,385 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 28.1, revenue per share of 36.96
and a 15.56% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on: